The fine comes as the DNA testing firm, which filed for bankruptcy in March, is set to be sold to a new owner.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Privacy and information commissioners from Canada and the U.K. will reveal the findings of their investigation into the 23andMe data breach.

The stock's fall snapped a two-day winning streak.

A U.S.-based Nigerian and visionary in geoscience and data innovation, Mathew Ogieva, has continued to leave an indelible mark on global Science, ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Mr Mathew Ogieva, a U.S.-based Nigerian and visionary in geoscience and data innovation, has continued to leave an indelible ...

A 23andMe booth at a genealogical event. The Canadian and British commissioners found the company did not have adequate ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...